NCT06577402

Brief Summary

Evaluation of early energy metabolism and muscle mass changes in patients with severe brain injury, the impact of nutritional therapy on metabolism and muscle mass, and their relationship with patient prognosis, to provide clinical research references for the implementation of individualized nutritional therapy in patients with severe brain injury.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
6

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 15, 2024

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 27, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 29, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2025

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2025

Completed
Last Updated

August 29, 2024

Status Verified

August 1, 2024

Enrollment Period

1 year

First QC Date

August 27, 2024

Last Update Submit

August 27, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Basal Metabolic Rate

    first 10 day

Interventions

nutritional supportDIETARY_SUPPLEMENT

nutritional support

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients with critical neurological illness

You may qualify if:

  • Patients with severe neurological critical illness admitted to the ICU, including moderate to severe acute cerebrovascular disease, severe acute craniocerebral injury and spinal cord injury, central nervous system bacterial infections, status epilepticus, neurosurgical patients requiring life support during the perioperative period, and other progressive severe neurological conditions.
  • Age ≥ 18 years old.
  • Receiving invasive mechanical ventilation.
  • Willing to sign an informed consent form.

You may not qualify if:

  • Women of childbearing age with a positive pregnancy test, pregnant, or lactating women.
  • Chronic diseases with severe organ dysfunction or serious complications:
  • Heart: New York Heart Association (NYHA) Functional Classification IV.
  • Lung: Chronic respiratory failure requiring long-term oxygen therapy.
  • Kidney: Chronic kidney disease stage 4 or 5; Liver: History of liver failure, hepatic encephalopathy, or hepatic coma, recent gastrointestinal bleeding due to portal hypertension, or Child-Pugh score ≥ 10.
  • Cancer patients with cachexia, or with severe organ dysfunction due to obstruction, mass effect, compression, or those who have not undergone surgery due to difficulty or recent chemotherapy or immunotherapy within one month.
  • Severe immunodeficiency or current use of potent immunosuppressants, agranulocytosis (N \< 0.5×10\^9/L), active hematologic malignancy, or HIV infection stage III; currently undergoing immunosuppressive induction therapy, such as antithymocyte globulin (ATG), antilymphocyte globulin (ALG), interleukin 2 receptor alpha chain antibody (IL-2RA), interleukin 6 receptor A antibody (IL-6RA), etc.; continuous use of glucocorticoids for more than 2 weeks, with a daily dose exceeding the equivalent of 200 mg of hydrocortisone.
  • Acute gastrointestinal injury (AGI) grade IV, such as intestinal ischemia and necrosis, gastrointestinal bleeding leading to hemorrhagic shock, abdominal compartment syndrome (IAP \> 20mmHg) requiring active decompression, etc.
  • Implanted with life-sustaining devices such as a pacemaker.
  • In a critical condition with an expected survival time of less than 24 hours.
  • Receiving or requiring dialysis or renal replacement therapy within 6 hours (this time frame is considered to exclude patients who may have acute changes in renal function that could confound the study outcomes or who may be in a transient state that could resolve without the need for long-term dialysis or renal replacement therapy).
  • Patients requiring or currently receiving extracorporeal membrane oxygenation (ECMO) treatment.
  • Combined with severe and above burns: total body surface area of burns exceeding 30% or III-degree burns area exceeding 10%; or with a total area of less than 30%, but with a severe overall condition or in shock, combined injuries, or respiratory tract burns.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongda Hospital, Southeast university

Nanjing, Jiangsu, China

RECRUITING

MeSH Terms

Interventions

Nutritional Support

Intervention Hierarchy (Ancestors)

Nutrition TherapyTherapeutics

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
30 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending Physician

Study Record Dates

First Submitted

August 27, 2024

First Posted

August 29, 2024

Study Start

April 15, 2024

Primary Completion

April 15, 2025

Study Completion

December 15, 2025

Last Updated

August 29, 2024

Record last verified: 2024-08

Locations